[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1108196T1 - Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα - Google Patents

Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα

Info

Publication number
CY1108196T1
CY1108196T1 CY20081100739T CY081100739T CY1108196T1 CY 1108196 T1 CY1108196 T1 CY 1108196T1 CY 20081100739 T CY20081100739 T CY 20081100739T CY 081100739 T CY081100739 T CY 081100739T CY 1108196 T1 CY1108196 T1 CY 1108196T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
oral
antimicrobial pharmaceutical
administrated
antimicrobial
Prior art date
Application number
CY20081100739T
Other languages
English (en)
Inventor
Mauro Aiani
Roberta Bozzella
Giuseppe Celasco
Roberto Villa
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of CY1108196T1 publication Critical patent/CY1108196T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε χορηγούμενες από το στόμα φαρμακευτικές συνθέσεις με ελεγχόμενη και/ή προγραμματισμένη αποδέσμευση που περιλαμβάνουν τουλάχιστον ένα ενεργό συστατικό με αντιμικροβιακή και/ή αντι-λοιμογόνο δράση για τη θεραπευτική αντιμετώπιση λοιμώξεων του παχέος εντέρου, ειδικότερα δε στο κόλον.
CY20081100739T 2004-06-25 2008-07-14 Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα CY1108196T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001295A ITMI20041295A1 (it) 2004-06-25 2004-06-25 Composizioni farmaceutiche antimicrobiche orali
EP05749954A EP1763339B1 (en) 2004-06-25 2005-05-03 Oral antimicrobial pharmceutical compositions

Publications (1)

Publication Number Publication Date
CY1108196T1 true CY1108196T1 (el) 2014-02-12

Family

ID=34968899

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100739T CY1108196T1 (el) 2004-06-25 2008-07-14 Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα

Country Status (22)

Country Link
US (9) US8486446B2 (el)
EP (2) EP1763339B1 (el)
JP (2) JP5026262B2 (el)
KR (2) KR101157486B1 (el)
CN (2) CN101317826A (el)
AT (1) ATE392889T1 (el)
CA (2) CA2569683C (el)
CY (1) CY1108196T1 (el)
DE (1) DE602005006278T2 (el)
DK (1) DK1763339T3 (el)
ES (1) ES2303255T3 (el)
FI (1) FIC20190031I1 (el)
HR (1) HRP20080252T3 (el)
HU (1) HUS1900037I1 (el)
IT (1) ITMI20041295A1 (el)
MX (1) MXPA06014698A (el)
PL (1) PL1763339T3 (el)
PT (1) PT1763339E (el)
RS (1) RS50581B (el)
SI (1) SI1763339T1 (el)
WO (1) WO2006003043A1 (el)
ZA (1) ZA200610577B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2420226B1 (en) † 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
BRPI1006145B8 (pt) 2009-01-12 2021-05-25 Biokier Inc composição e método para tratamento de diabetes
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011038014A2 (en) 2009-09-23 2011-03-31 Biokier, Inc. Composition and method for treatment of diabetes
WO2012016707A2 (en) * 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form for the modified release of dimebolin
WO2012075015A2 (en) * 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
DK3706724T3 (da) 2017-11-10 2024-10-14 Cosmo Technologies Ltd Orale rifamycin-sv-sammensætninger
IT202000005782A1 (it) 2020-03-18 2021-09-18 Dpl Pharma S P A Formulazioni farmaceutiche a rilascio controllato per il trattamento di infezioni intestinali
KR102714380B1 (ko) * 2021-06-09 2024-10-11 강원대학교산학협력단 경구 투여용 나노입자 및 이의 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE458505B (sv) * 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
CN1097306A (zh) * 1993-07-12 1995-01-18 中国医科大学第二临床学院 复方抗炎栓剂
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5985823A (en) * 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
KR100446366B1 (ko) * 1997-07-01 2004-09-01 화이자 인코포레이티드 서트랄린 염 및 서트랄린의 서방성 투여형
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9910773D0 (en) * 1999-05-11 1999-07-07 West Pharm Serv Drug Res Ltd Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
JP4790950B2 (ja) * 1999-06-14 2011-10-12 コスモ・テクノロジーズ・リミテッド 制御放出および味感遮蔽経口医薬組成物
JP4393098B2 (ja) 2002-06-21 2010-01-06 独立行政法人科学技術振興機構 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
CN1201736C (zh) * 2002-07-19 2005-05-18 安徽省药物研究所 甲硝唑结肠定位缓释制剂
AU2003260736B8 (en) * 2002-08-26 2009-04-23 S.L.A. Pharma Ag A pharmaceutical composition
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations

Also Published As

Publication number Publication date
DE602005006278T2 (de) 2009-10-08
CA2628005A1 (en) 2006-01-12
US20070248664A1 (en) 2007-10-25
US8529945B2 (en) 2013-09-10
US20080233193A1 (en) 2008-09-25
ATE392889T1 (de) 2008-05-15
RS50581B (sr) 2010-05-07
EP1894560A1 (en) 2008-03-05
WO2006003043A1 (en) 2006-01-12
US20120316229A1 (en) 2012-12-13
US8486446B2 (en) 2013-07-16
US20130004569A1 (en) 2013-01-03
JP2008163038A (ja) 2008-07-17
US20140370093A1 (en) 2014-12-18
KR20080059337A (ko) 2008-06-26
US20190192441A1 (en) 2019-06-27
KR101157486B1 (ko) 2012-07-09
CA2569683C (en) 2012-04-03
HRP20080252T3 (en) 2008-07-31
PL1763339T3 (pl) 2008-10-31
US20210093576A1 (en) 2021-04-01
ZA200610577B (en) 2008-07-30
SI1763339T1 (sl) 2008-08-31
EP1763339B1 (en) 2008-04-23
CN101317826A (zh) 2008-12-10
ES2303255T3 (es) 2008-08-01
FIC20190031I1 (fi) 2019-05-28
US20120207834A1 (en) 2012-08-16
CN1976685B (zh) 2011-05-18
CN1976685A (zh) 2007-06-06
CA2569683A1 (en) 2006-01-12
DE602005006278D1 (de) 2008-06-05
US8263120B2 (en) 2012-09-11
ITMI20041295A1 (it) 2004-09-25
JP2008503540A (ja) 2008-02-07
MXPA06014698A (es) 2007-03-26
EP1763339A1 (en) 2007-03-21
DK1763339T3 (da) 2008-08-11
JP5026262B2 (ja) 2012-09-12
US20120316228A1 (en) 2012-12-13
HUS1900037I1 (hu) 2019-07-29
KR20070028441A (ko) 2007-03-12
US8741948B2 (en) 2014-06-03
PT1763339E (pt) 2008-06-19

Similar Documents

Publication Publication Date Title
CY1108196T1 (el) Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα
CY1118179T1 (el) Φαρμακευτικη συνθεση
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
ATE536172T1 (de) Ezetimibzusammensetzungen
AR050717A1 (es) Composiciones farmaceuticas
ATE537828T1 (de) Psychotropes mittel und nahrungsmittel zur förderung der gesundheit enthaltend neferin
NO20076405L (no) Anvendelse av 24-nor-UDCA
DE602005011240D1 (de) Landwirtschaftliche desinfizierende Zusammensetzung enthaltend Hypochlorsäure und Streumittel
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
DK1666473T3 (da) Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
DK1838716T3 (da) Olanzapinpamota-dihydrat
ITBO20050416A1 (it) Composizione per la cura e/o la prevenzione di attacchi da parte di agenti biologici
CL2020000124A1 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.
DK1827496T3 (da) Orale behandlingssammensætninger indeholde et antiadhæsionsmiddel, et antibakterielt middel og en inkompatibel forbindelse
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
UY31954A (es) 3-(n-heterociclil)-pirrolidinil-fenil-oxazolidinonas como agentes antibacterianos
ATE505193T1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
CL2004000753A1 (es) Compuestos derivados de oxazolidinona y/o isoxazolina, composicion farmaceutica, procedimiento de preparacion, utiles como antibacterianos.
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung